No Data
No Data
Recent Uptick Might Appease Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Owners After Losing 66% Over the Past Year
$FATE Stock Is up 12% Today. Here's What We See in Our Data.
Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall
Fate Therapeutics Receives RMAT Designation From FDA for FT819
Express News | Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (Sle)
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)